Chemotherapy

Cisplatin-Induced Adverse Events in Osteosarcoma Not Improved With Pantoprazole

Cisplatin-Induced Adverse Events in Osteosarcoma Not Improved With Pantoprazole

By

This phase 2 study sought to determine whether concurrent pantoprazole would improve cisplatin-induced ototoxicity and nephrotoxicity in younger patients with osteosarcoma.

Efficacy and Safety of COX-2 Inhibitors for Advanced Non-small-cell Lung Cancer With Chemotherapy: A Meta-analysis

Efficacy and Safety of COX-2 Inhibitors for Advanced Non-small-cell Lung Cancer With Chemotherapy: A Meta-analysis

[OncoTargets and Therapy] This meta-analysis assesses the efficacy and safety profile of COX-2 inhibitors in patients with advanced non-small-cell lung cancer.

Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer

Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer

By

In a secondary analysis of the BEATE and INVEST study, researchers followed a link between levothyroxine use, exercise, and fatigue in women with breast cancer undergoing chemotherapy.

Adjuvant Gemcitabine Regimen Improves PFS in Upper Tract Urothelial Cancer

Adjuvant Gemcitabine Regimen Improves PFS in Upper Tract Urothelial Cancer

By

Investigators compared adjuvant gemcitabine plus cisplatin vs surveillance and subsequent chemotherapy if needed for patients who underwent nephron-ureterectomy for UTUC.

Pomalidomide Plus Dexamethasone Effective in R/R Multiple Myeloma

Pomalidomide Plus Dexamethasone Effective in R/R Multiple Myeloma

By

Researchers report on their findings of a retrospective study that compared pomalidomide plus dexamethasone vs dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Preoperative Treatment for Gastric Cancer Varies by Race, Ethnicity

Preoperative Treatment for Gastric Cancer Varies by Race, Ethnicity

By

Researchers conducted a retrospective study of US patients with gastric cancer to determine what factors influenced the use of preoperative chemotherapy in this patient population.

Breast Cancer Therapies Associated With Increased Risk for Cardiovascular Disease

Breast Cancer Therapies Associated With Increased Risk for Cardiovascular Disease

By

Advances in breast cancer treatment are improving outcomes for patients with the disease; however, treatments are increasing these patients' risk for cardiovascular diseases.

Cardiotoxicity Risk Greater in Blacks With Breast Cancer Receiving HER2 Therapies

Cardiotoxicity Risk Greater in Blacks With Breast Cancer Receiving HER2 Therapies

By

Retrospective study examines the association between risk of cardiotoxicity and race in women with breast cancer receiving chemotherapy and at least 1 year of HER2-targeted therapy.

Oral Impairment Linked to Reduced QOL in Posttherapy Head and Neck Cancer

Oral Impairment Linked to Reduced QOL in Posttherapy Head and Neck Cancer

By

Study compared the effect of treatments on quality of life in treatment-naïve patients with HNC vs those who underwent radiotherapy and/or chemotherapy, and compared with cancer-free patients.

Chemotherapy Toxicity Risk Score Use Improved Treatment Choice for Elderly

Chemotherapy Toxicity Risk Score Use Improved Treatment Choice for Elderly

By

This observational study demonstrates the significance of using the chemotherapy toxicity risk score (CTRS) to determine if an elderly patient can safely tolerate standard-dose combination chemotherapy, or would fare better with a reduced-dose regimen.

Antenatal Cancer Therapy Associated With Specific Neonatal Complications

Antenatal Cancer Therapy Associated With Specific Neonatal Complications

By

Cohort study assessed the effect of antenatal cancer treatment on specific neonatal complications by type of chemotherapy and by type of cancer.

Patient Support Program Provides Diversions During Chemotherapy Infusions

Patient Support Program Provides Diversions During Chemotherapy Infusions

By

A kind gesture toward friends during their chemotherapy infusions developed into a support organization that helps patients pass the time during their treatment.

Hyperthermic intraperitoneal chemotherapy with surgery increases survival for epithelial ovarian cancer patients

1. Patients with stage 3 epithelial ovarian cancer treated with hyperthermic intraperitoneal chemotherapy (HIPEC) in addition to cytoreductive surgery and neoadjuvant chemotherapy experienced increased overall and recurrence-free survival compared to those treated with surgery and chemotherapy alone. 2. No difference in grade 3 or 4 adverse side effects were observed between HIPEC and non-HIPEC treated []

OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer

OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer

By

In a phase 3 study presented at the 2018 Gastrointestinal Cancers Symposium, researchers reported on OS outcomes with gemcitabine plus S-1 vs gemcitabine plus cisplatin in patients with advanced biliary tract cancer.

Overall Survival Prolonged With HIPEC + Cytoreductive Surgery for Gastric Cancer

Overall Survival Prolonged With HIPEC + Cytoreductive Surgery for Gastric Cancer

By

Data presented at the 2018 Gastrointestinal Cancers Symposium compared overall survival with cytoreductive surgery (CRS) alone for patients with gastric cancer and peritoneal carcinomatosis vs treatment with HIPEC plus CRS.

Anxiety, Depression Higher, QOL Lower Between Chemotherapy Cycles for Breast Cancer

Anxiety, Depression Higher, QOL Lower Between Chemotherapy Cycles for Breast Cancer

By

A longitudinal study assessed psychological status of postoperative patients with breast cancer between adjuvant chemotherapy for anxiety and depression.

Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers

Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers

By

The US FDA approved pertuzumab in combination with trastuzumab and chemotherapy for adjuvant treatment of HER2-positive early breast cancer, and converted accelerated to full approval for the regimen as neoadjuvant therapy in certain breast cancers.

Pazopanib Plus Paclitaxel Does Not Improve Outcomes in Recurrent Ovarian Cancer

Pazopanib Plus Paclitaxel Does Not Improve Outcomes in Recurrent Ovarian Cancer

By

Results of a double-blind phase 2 study determined if adding oral pazopanib to intravenous paclitaxel improved outcomes for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

Sarcopenia Severity Prognostic of Postchemotherapy Outcomes in the Elderly

Sarcopenia Severity Prognostic of Postchemotherapy Outcomes in the Elderly

By

Using a series of functional tests, researchers determined the significance of sarcopenia severity after chemotherapy in older patients with cancer and its effect on their physical independence.

Hearing Loss, Tinnitus May Predict Worse Outcomes for Cancer Survivors

Hearing Loss, Tinnitus May Predict Worse Outcomes for Cancer Survivors

By

A survey of 754 cancer survivors sought to determine the association between number of neurotoxicities such as CIN, hearing loss, and tinnitus and outcomes for these patients.

Exercise Reduces Severity of Chemotherapy-Induced Peripheral Neuropathy

Exercise Reduces Severity of Chemotherapy-Induced Peripheral Neuropathy

By

For this study, researchers sought to determine the effect exercise would have on severity of symptoms for patients who develop CIPN after taxane, platinum, or vinca alkaloid based chemotherapy.

High-Dose Dexamethasone Effective With Less Adverse Effects in ITP vs Corticosteroids

High-Dose Dexamethasone Effective With Less Adverse Effects in ITP vs Corticosteroids

By

In this randomized trial, investigators sought to determine the effectiveness of high-dose dexamethasone vs conventional prednisone therapy in treatment-naïve patients with ITP. Results were presented at ASH 2017.

Incorporating Cardiac Care in the Oncology Setting

Incorporating Cardiac Care in the Oncology Setting

By

Cardio-oncology is an emerging interdisciplinary practice poised to address care patients who need concurrent cancer and cardiovascular disease therapies as well as the late effects of cancer and cancer treatments.

Fosaprepitant Improves Standard Antiemetic Therapy in Pediatric Patients

Fosaprepitant Improves Standard Antiemetic Therapy in Pediatric Patients

By

Data presented at ASH 2017 illustrates the effectiveness of 2 prophylactic antiemetic regimens in pediatric patients receiving moderately or highly emetogenic chemotherapy.

Current Findings in Trial Evaluating Paclitaxel Substitution in Invasive Breast Cancer

Current Findings in Trial Evaluating Paclitaxel Substitution in Invasive Breast Cancer

By

Researchers presented an update of findings in the GeparSepto trial, which seeks to determine whether improvements in pathologic complete response can be translated to a survival benefit, at SABCS 2017.

Best Antiemetic Therapies for Alleviating CINV: A Literature Review

Best Antiemetic Therapies for Alleviating CINV: A Literature Review

By

A review of 12 antiemetic regimens identified 3 that may be more effective than conventional regimens, a study presented at SABCS 2017 has shown.

Prolonging Survival in MM: Daratumumab vs Pomalidomide Plus Dexamethasone

Prolonging Survival in MM: Daratumumab vs Pomalidomide Plus Dexamethasone

By

A head-to-head comparison investigated whether patients with multiple myeloma achieved greater prolongation in overall survival with daratumumab monotherapy or pomalidomide plus low-dose dexamethasone.

Markers Identified for Cardiotoxicity Due to Chemotherapy for Breast Cancer

Markers Identified for Cardiotoxicity Due to Chemotherapy for Breast Cancer

By

Biomarker analysis revealed markers for cardiotoxicity enabling early initiation of heart failure therapy in patients with breast cancer who were treated with chemotherapy.

4R+3Dex Regimen May Lead to Durable Complete Response in Pediatric Chronic ITP

4R+3Dex Regimen May Lead to Durable Complete Response in Pediatric Chronic ITP

By

Young patients with chronic ITP may experience relapse within 5 years of completing therapy. In this study, investigators sought to determine if the 4R+3Dex regimen for chronic ITP would improve response rates in pediatric patients with the disease.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs